AcelRx Pharmaceuticals

AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's DSUVIA? and Zalviso, are both focused on the treatment of acute pain, and each utilize sufentanil, for use in medically supervised settings. DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Zalviso is for the management of moderate-to-severe acute pain in hospitalized adult patients.
  • TickerACRX
  • ISINUS00444T1007
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Thanks to a better fundamental star rating, ACELRX PHARMACEUTICALS sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ACELRX PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 12, 2021, the closing price was USD 2.18 and its expected value was estimated at USD 1.42.

Jonathan Moreland

InsiderInsights Daily Ratings Report: June 15, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

Jonathan Moreland

InsiderInsights Daily Ratings Report: June 15, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Thanks to a better fundamental star rating, ACELRX PHARMACEUTICALS sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ACELRX PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 12, 2021, the closing price was USD 2.18 and its expected value was estimated at USD 1.42.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch